Inflammatory bowel disease new-onset during secukinumab therapy: real-world data from a tertiary center

Rev Esp Enferm Dig. 2021 Oct 26. doi: 10.17235/reed.2021.8397/2021. Online ahead of print.

Abstract

Secukinumab is a monoclonal antibody that inhibits interleukin - 17A. It is currently prescribed for the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis, which are immune-mediated diseases that show significant co-heritability with IBD. Although this treatment appears to be well tolerated by patients, during the last years, several cases of new- onset IBD after secukinumab have been reported.